首页> 外文期刊>Annals of Surgery >Outcomes of Endovascular Repair for Abdominal Aortic Aneurysms
【24h】

Outcomes of Endovascular Repair for Abdominal Aortic Aneurysms

机译:腹主动脉瘤血管内修复结果

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To analyze data on patients treated with a bifurcated stent graft for abdominal aortic aneurysm (AAA). Background: The Japan Committee for Stentgraft Management (JACSM) was established in 2007 to manage the safety of endovascular aortic aneurysm repair (EVAR) in Japan. The JACSM registry includes detailed anatomical and clinical data of all patients who undergo stent graft insertion in Japan. Methods: Among 51,380 patients treated with bifurcated stent graft for AAA, we identified 38,008 eligible patients (excluding those with rupture or insufficient data). The analyzed factors included age, sex, comorbidities, AAA pathology and etiology, aneurysm and neck diameters, 7 anti-instructions for use (IFU) factors, and endoleaks at hospital discharge. The endpoints were death, adverse events, sac dilatation (≥5?mm), and reintervention. Results: The rates of intraoperative and in-hospital mortality were 0.08% and 1.07%, respectively. Infectious aneurysm and pseudo-aneurysm were associated with overall survival and reintervention. Older age, large aneurysm diameter, and all types of persistent endoleaks were strong predictors of adverse events, sac dilatation, and reintervention. Comorbid cerebrovascular disease, renal dysfunction, and respiratory disorders were also risk factors. In total, 47.6% of patients violated the IFU; among the anti-IFU factors assessed, poor access and severe neck calcification were strong risk factors for mortality, reintervention, and adverse events. The sac dilatation rate at 5 years was 23.3%. Conclusions: Although the analysis included EVAR with poor anatomy, the perioperative mortality rate was acceptable compared with that in previous large population studies.
机译:目的:分析腹主动脉瘤(AAA)对分叉支架移植物治疗的患者数据。背景:日本Stentrover管理委员会(JACSM)成立于2007年,以管理日本血管内主动脉瘤修复(EVAR)的安全性。 JACSM注册机构包括在日本接受支架移植物插入的所有患者的详细解剖和临床数据。方法:51,380名患者对AAA分叉支架移植物治疗,我们确定了38,008名符合条件的患者(不包括破裂或数据不足的患者)。分析的因素包括年龄,性别,组合,AAA病理学和病因,动脉瘤和颈部直径,7例防杆菌(IFU)因子,以及医院排放的螺旋迹。终点是死亡,不良事件,囊扩张(≥5Ωmm)和重新实施。结果:术中和住院死亡率分别为0.08%和1.07%。传染性动脉瘤和假动脉瘤与整体生存和重新入住有关。年龄较大,大动脉瘤直径,所有类型的持久性延期胚胎是不良事件,囊扩张和重新入养的强预测因子。共血管脑血管病,肾功能不全和呼吸系统障碍也是危险因素。共有47.6%的患者侵犯了IFU;在评估的抗IFU因素中,差的接入和严重的颈部钙化是死亡,重新营养和不良事件的强风险因素。 5岁的囊膨胀率为23.3%。结论:虽然分析包括避免解剖学差,但与以往的大群研究相比,围手术期死亡率是可接受的。

著录项

  • 来源
    《Annals of Surgery》 |2019年第3期|共10页
  • 作者单位

    Department of Vascular Surgery Graduate School of Medicine The University of Tokyo Tokyo Japan;

    Division of Cardiovascular Surgery Department of Surgery Toda Chuo General Hospital Saitama;

    Department of Health Services Research Graduate School of Medicine the University of Tokyo Tokyo;

    Department of Clinical Epidemiology and Health Economics School of Public Health the University;

    Divison of Vascular Surgery Department of Surgery Nagoya University Graduate School of Medicine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 外科学;
  • 关键词

    EVAR; JACSM; Japan; registry; stent graft;

    机译:EVAR;JACSM;日本;登记处;支架移植物;
  • 入库时间 2022-08-20 01:21:02

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号